KRIYA-586 / Kriya Therap - LARVOL DELTA

Development and Evaluation of AAV9.anti-IGF1R (Insulin-like Growth Factor-1 Receptor) Vector Potency Methods for KRIYA-586, a One-time Gene Therapy for Thyroid Eye Disease (TED). (ASGCT 2025) - "The KRIYA-586 potency assessment successfully demonstrated a robust evaluation of AAV vector transduction and therapeutic protein activity. The approach of using a simplified Quality-Control feasible cell line yielded comparable biological activity measurements to those obtained from a more biologically relevant cell line, validating a more efficient approach to vector potency testing. This analytical framework allows characterization of vector functionality prior to release, while maintaining feasibility for routine testing in a GMP environment."

Gene therapy • Gene Therapies • Infectious Disease • Ocular Inflammation • Ophthalmology • Thyroid Eye Disease • IGF1R

Inhibition of IGF1R with KRIYA-586: A Novel AAV Gene Therapy Expressing an Anti-IGF1R Antibody Demonstrates Comparable Pharmacodynamic Activity to Teprotumumab (ASGCT 2025) - "This supports further evaluation of the potential translation of KRIYA-586 gene therapy to impact the course of TED. Disease Focus of Abstract:Eye Disorders"

Gene therapy • PK/PD data • Colon Cancer • Colorectal Cancer • Diabetes • Fibrosarcoma • Gene Therapies • Ocular Inflammation • Oncology • Ophthalmology • Sarcoma • Solid Tumor • Thyroid Eye Disease • IGF1R

Kriya Announces Thirteen Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2025 (GlobeNewswire) - "Kriya Therapeutics, Inc...announced thirteen presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, which will be held May 13 to 17, 2025 in New Orleans, LA."

PK/PD data • Preclinical • Diabetes • Immunology • Macular Degeneration • Thyroid Eye Disease

Kriya Highlights Positive Preclinical Data for KRIYA-586, a Gene Therapy Product Candidate for Thyroid Eye Disease (TED), at ESOPRS Annual Meeting (GlobeNewswire) - "Kriya Therapeutics...announced preclinical data from its gene therapy program for thyroid eye disease (TED). The data are being presented at the 42nd Annual Meeting of the European Society of Ophthalmic Plastic & Reconstructive Surgery (ESOPRS)....The study demonstrated: A vectorized antibody capable of blocking IGF1R to a similar degree as teprotumumab; and In a preclinical in vivo model, anti-IGF1R antibody produced by KRIYA-586 demonstrated a similar reduction in levels of IGF1R and downstream activity as teprotumumab....Kriya anticipates advancing KRIYA-586 into the clinic in 2025 to evaluate its safety and efficacy in people suffering from TED."

New trial • Preclinical • Thyroid Eye Disease